Frontlight ResearchEarly access
CompletedPhase 3
Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia
Key facts
- Who runs it
- Jiangsu HengRui Medicine Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 240 people enrolled
- Started
- 5 Mar 2019
- Ended
- 3 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Hetrombopag Olamine+Standard Therapy
- Placebo+Standard Therapy
- Record updated
- 7 November 2024
Who can take part
- Age
- 15 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (18)Hide the full registry criteria
Who can take part
- 1.15 Years to 75 Years (weight greater than 50 kg if Age < 18 years old). 2.Severe aplastic anemia characterized by Bone marrow cell proliferation less than 25 percent (If ≥25% but <50%, the remaining hematopoietic cells should be <30%) AND At least two of the following: Absolute neutrophil count <0.5×109/L; Platelet count <20×109/L; Absolute reticulocyte count <20×109/L
- 3.Unsuitable or unwilling to perform hematopoietic stem cell transplantation (HSCT)
- 4.Signed informed consent
Who cannot take part
- Subjects who have previously received immunosuppressive therapy with mycophenolate mofetil, sirolimus, high dose cyclophosphamide (≥45mg/kg/d), alemtuzumab, etc;or have treated with thrombopoietin receptor agonist (eg, eltrombopag, romiplostim, rhTPO, etc.) prior to randomization
- Previous history of hematopoietic stem cell transplantation
- Subjects with malignant solid tumors of any organ system within 5 years prior to screening, with or without treatment, metastasis or recurrence, except for local cutaneous basal cell carcinoma; subjects with hematological tumors found previously or during screening
- Subjects with deep vein thrombosis, myocardial infarction, stroke or peripheral arterial embolization within 12 months prior to randomization
- Subjects have participated in other clinical trial within the 3 months prior to study entry
- Diagnosis of whole blood cell reduction due to other causes or bone marrow hypoproliferative diseases
- Subjects who is known or suspected of contraindications or hypersensitivity to Hetrombopag's API (Active Pharmaceutical Ingredient)
- Bleeding and/or Infection not adequately responding to appropriate therapy
- Subjects diagnosed with cirrhosis or portal hypertension
- Any laboratory or clinical evidence for HIV infection. Any clinical history for hepatitis C infection; chronic hepatitis B infection; or any evidence for active hepatitis at the time of subjects screening
- ALT> 2.5 x upper limit of normal (ULN), AST> 2.5 x upper limit of normal (ULN) DBLI> 1.5 x upper limit of normal (ULN), Scr> upper limit of normal (ULN)
- Subjects with uncontrolled hypertension (>180/100mmHg), severe arrhythmia (such as complete left bundle branch block, QT interval prolongation (Bazetts formula), torsade ventricular tachycardia, etc.), unstable angina, pulmonary hypertension at the time of screening
- Evidence of clonal cytogenetic abnormalities at the time of screening
- Female subjects who are nursing or pregnant
- Subjects cannot comply with effective contraception
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, randomized, placebo-control, phase III study to investigate hetrombopag in subjects with severe AA who are treated naive.
Read full original descriptionShow less
180 treated naive patients with SAA will be enrolled in the study. The primary objective of the study will be the rate of complete hematologic response at six months.
The 2 groups in the trial
- Hetrombopag Olamine+Standard TherapyTreatment being tested
- Placebo+Standard TherapyPlacebo, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III Multicenter Randomized Study of Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia
- Record updated
- 7 November 2024